Roche Investor Relations ASCO Planner 2014

Transcription

1 Roche Investor Relations ASCO Planner 2014 F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations Tel Fax

2 2014 ASCO Annual Meeting Friday, May 30 Session Title: Lymphoma and Plasma Cell Disorders Date: Fri, May 30 Location: S405 Chair and/or Co-Chairs: Steven M. Horwitz, MD, and Sagar Lonial, MD Poster Board: #2 Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. (Abstract #8522) Matthew Steven Davids Session Title: Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics Date: Fri, May 30 Location: E354b Chair and/or Co-Chairs: Luis A. Diaz, MD, and Thehang H. Luu, MD Poster Board: #40 Results from the first-in-human (FIH) phase I study of RO (RG7221), a novel bispecific human anti-ang-2/anti-vegf-a antibody, administered as an intravenous infusion to patients with advanced solid tumors. (Abstract #2525) Manuel Hidalgo Saturday, May 31 Session Title: Targeted Therapies in Early, Mid, and Late Development Time: 1:15 PM - 2:45 PM Chair and/or Co-Chairs: Andrew D. Zelenetz, MD, PhD, and Michael E. Williams, MD 1:39 PM - 1:51 PM Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non- Hodgkin lymphoma (NHL). (Abstract #8519) Franck Morschhauser 1:51 PM - 2:03 PM Antibody Drug Conjugates as Therapies for Lymphomas Ronald Levy

3 Session Title: Leukemia, Myelodysplasia, and Transplantation Location: S405 Time: 1:15 PM - 4:15 PM Chair and/or Co-Chairs: Ronan T. Swords, MD, and Hongtao Liu, MD, PhD Poster Board: #5 ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. (Abstract #7013) Shuo Ma Poster Board: #7 ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control. (Abstract #7015) John Francis Seymour Session Title: Lung Cancer - Non-small Cell Metastatic Session Type: General Poster Session Location: S Hall A2 Time: 1:15 PM - 5:00 PM Poster Board: #284 Antitumor activity of alectinib (CH /RO ) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. (Abstract #8103) Kazuhiko Nakagawa Poster Board: #301B Clinical trials of MPDL3280A (anti-pdl1) in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #TPS8123) Naiyer A. Rizvi Session Title: Unleashing the Immune System in Genitourinary Cancers Time: 3:00 PM - 4:30 PM Chair and/or Co-Chairs: Sumanta K. Pal, MD 3:36 PM - 3:48 PM Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). (Abstract #5011) Thomas Powles 4:00 PM - 4:12 PM PD-1/PD-L1 Inhibition: Identifying Relevant Biomarkers Padmanee Sharma 4:12 PM - 4:30 PM Panel Question and Answer Panel Discussion

4 Sunday, June 1 Session Title: Sarcoma Location: S406 Time: 8:00 AM - 11:00 AM Chair and/or Co-Chairs: Hussein A. Tawbi, MD, PhD, and Roberta Sanfilippo, MD 9:12 AM - 9:24 AM Phase 1 study of RG7155, a novel anti-csf1r antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS). (Abstract #10504^) Philippe Alexandre Cassier Session Title: Immunobiology and Immunotherapy Location: S100bc Time: 11:30 AM - 1:00 PM Chair and/or Co-Chairs: Robert L. Ferris, MD, PhD 11:30 AM - 11:45 AM Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. (Abstract #6009) Vassiliki Saloura Session Title: Plenary Session Including the Science of Oncology Award and Lecture Session Type: Plenary Session Location: N Hall B1 Chair and/or Co-Chairs: Clifford A. Hudis, MD, FACP, and Jedd D. Wolchok, MD, PhD 2:45 PM - 3:00 PM CALGB/SWOG 80405: Phase III trial of irinotecan/5-fu/leucovorin (FOLFIRI) or oxaliplatin/5- FU/leucovorin (mfolfox6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). (Abstract #LBA3) Alan P. Venook 3:00 PM - 3:15 PM Discussion Josep Tabernero 6.00pm-8.00 PM Roche Analyst Meeting Marriott Downtown Chicago Chicago A-D (Level 5) 540 North Michigan Avenue Chicago

5 Monday, June 2 Session Title: Lung Cancer - Non-small Cell Metastatic Date: Mon, Jun 2 Location: E Hall D2 Time: 3:00 PM - 6:00 PM Chair and/or Co-Chairs: Grace K. Dy, MD, and Egbert F. Smit, MD, PhD 3:00 PM - 3:12 PM Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. (Abstract #8000) David R. Spigel 3:24 PM - 3:36 PM Two Faces of MET Federico Cappuzzo 3:36 PM - 3:48 PM Panel Question and Answer Panel Discussion 4:12 PM - 4:24 PM Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (Abstract #8005) Terufumi Kato Session Title: Melanoma/Skin Cancers Date: Mon, Jun 2 Time: 3:00 PM - 6:00 PM Chair and/or Co-Chairs: Jason J. Luke, MD, and Georgina V. Long, MD, PhD 4:36 PM - 4:48 PM Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma. (Abstract #9006^) Grant A. McArthur